Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
AcroCyte Therapeutics is advancing scalable human kidney organoid research through its ARPA-H-funded RACE programme, targeting new manufacturing capabilities for regenerative medicine and bioartificial kidney development. Representative image.
Pharma & Biotech

Can AcroCyte turn a $4.3m ARPA-H award into a scalable bioartificial kidney platform?

AcroCyte’s $4.3m ARPA-H-backed RACE project targets scalable autologous kidney organoids, but manufacturing and animal data remain the key tests.

Read More
Laboratory research into AbelZeta Pharma’s C-CAR031 armored GPC3 CAR-T therapy highlights the emerging potential and durability challenges of cellular treatment for advanced hepatocellular carcinoma. Representative image.
Pharma & Biotech

AbelZeta and AstraZeneca study identifies GPC3 loss as a potential C-CAR031 resistance mechanism

AbelZeta’s C-CAR031 study shows a 44.4% response rate in advanced liver cancer, but durability and resistance remain key tests.

Read More
Representative image: A retina specialist reviews advanced eye scans as Roche’s $RHHBY Susvimo moves closer to European approval, offering wet age-related macular degeneration patients a refillable implant designed to reduce frequent eye injections.
Pharma & Biotech

Roche gains positive CHMP opinion for Susvimo in wet age-related macular degeneration

Roche’s Susvimo wins a positive European opinion for wet AMD. See how two yearly refills could reduce injections and reshape retinal care.

Read More
A woman reviews an at-home HPV self-collection kit, illustrating how Teal Health and UC Davis Health aim to integrate cervical cancer screening into routine health-system care. Representative image.
Medical Devices & Diagnostics

How the Teal Health UC Davis pilot could reshape cervical cancer screening workflows

Teal Health and UC Davis Health test how FDA-authorized at-home HPV screening can fit routine care and reach overdue patients.

Read More
Apertura Gene Therapy’s TfR1 CapX delivery platform will support an ARPA-H-backed consortium developing gene-editing therapies for Dravet syndrome, alternating hemiplegia of childhood and other rare pediatric neurological diseases. Representative image.
Pharma & Biotech

Apertura joins $34.5m ARPA-H PERC program for rare pediatric CNS gene editing

Apertura joins Broad’s $34.5 million ARPA-H PERC program, pairing TfR1 CapX with gene editing for rare pediatric brain diseases.

Read More
AI-engineered enzymes, automated molecular testing and blood-based Alzheimer’s biomarker analysis illustrate Fapon’s ADLM 2026 strategy to support faster diagnostic development in North America. Representative image.
Medical Devices & Diagnostics

Fapon’s ADLM 2026 showcase looks bigger than a product launch. Here is the real diagnostics strategy

Fapon unveils AI-engineered PCR enzymes and Alzheimer’s biomarker reagents at ADLM 2026, targeting faster North American IVD development.

Read More
Maggie Q targets muscle resilience market with ActivatedYou Vital Strength
Pharma & Biotech

Maggie Q’s ActivatedYou is betting on creatine, but one ingredient will carry most of the scientific weight

ActivatedYou launches Vital Strength with 5 g creatine, BCAAs and vitamin D3, testing whether evidence-led dosing can win wellness consumers.

Read More
FDA clearance connects SurGenTec ION-L with Medtronic StealthStation workflow
Medical Devices & Diagnostics

SurGenTec’s ION-L can now connect with StealthStation, but will navigation unlock hospital adoption?

SurGenTec’s ION-L gains FDA-cleared StealthStation navigation compatibility, but adoption will depend on clinical proof and operating-room economics.

Read More
Robotic endoscopic surgery in a modern hospital setting illustrates EndoQuest Robotics’ PARADIGM trial milestone, as the company advances its investigational Endoluminal Surgical System toward a planned United States Food and Drug Administration De Novo submission. Representative image.
Medical Devices & Diagnostics

EndoQuest’s ELS robot posted striking early resection results. What will the FDA demand next?

EndoQuest completes PARADIGM enrollment with encouraging preliminary ESD results, setting up a critical FDA De Novo submission.

Read More
A clinician-scientist reviews ocular imaging as DYP688 Phase 1 results highlight early targeted activity in metastatic uveal melanoma, even as the drug’s future development remains uncertain. Representative image.
Pharma & Biotech

A promising eye cancer drug shrank tumors in phase 1, so why did Novartis stop developing DYP688?

DYP688 showed early activity and manageable toxicity in metastatic uveal melanoma, but Novartis has halted development despite the clinical signal.

Read More